Ensign Peak Advisors’s Theravance Biopharma TBPH Stock Holding History

Ensign Peak Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-60,907	Closed	-$573K	–	1726
2024 Q4	$573K	Hold	60,907	–	–	﹤0.01%	1557
2024 Q3	$491K	Hold	60,907	–	–	﹤0.01%	1612
2024 Q2	$516K	Hold	60,907	–	–	﹤0.01%	1592
2024 Q1	$546K	Sell	60,907 -3,073	-5%	-$28.5K	﹤0.01%	1603
2023 Q4	$719K	Hold	63,980	–	–	﹤0.01%	1550
2023 Q3	$552K	Buy	63,980 +7,250	+13%	+$70K	﹤0.01%	1561
2023 Q2	$587K	Hold	56,730	–	–	﹤0.01%	1586
2023 Q1	$616K	Buy	56,730 +9,150	+19%	+$96.8K	﹤0.01%	1573
2022 Q4	$534K	Buy	47,580 +22,750	+92%	+$239K	﹤0.01%	1603
2022 Q3	$252K	Hold	24,830	–	–	﹤0.01%	1783
2022 Q2	$225K	Hold	24,830	–	–	﹤0.01%	1757
2022 Q1	$237K	Hold	24,830	–	–	﹤0.01%	1832
2021 Q4	$274K	Buy	+24,830	New	+$216K	﹤0.01%	1843
2020 Q2	–	Sell	-6,081	Closed	-$141K	–	1698
2020 Q1	$141K	Sell	6,081 -6,081	-50%	-$152K	﹤0.01%	1563
2019 Q4	$315K	Buy	+12,162	New	+$236K	﹤0.01%	1586

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Ensign Peak Advisors's TBPH Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Theravance Biopharma (TBPH) in Q1 2025, closing a stake of 60,907 shares — an estimated $573K sold.

Ensign Peak Advisors first reported a position in TBPH in Q4 2019 and held it in 15 quarters. The position peaked at $719K in Q4 2023. 131 funds tracked by Wall St. Rank hold TBPH as of Q1 2025.

Ensign Peak Advisors reported no remaining Theravance Biopharma position as of Q1 2025 after selling out during the quarter.
Ensign Peak Advisors sold 60,907 Theravance Biopharma shares in Q1 2025, an estimated $573K.
Ensign Peak Advisors first reported a position in Theravance Biopharma in Q4 2019 and held it in 15 quarters.
Ensign Peak Advisors's Theravance Biopharma position peaked at $719K in Q4 2023.
131 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.